Allscripts Healthcare Solutions (NASDAQ:MDRX) versus The Competition Financial Review

Allscripts Healthcare Solutions (NASDAQ: MDRX) is one of 18 public companies in the “Medical Software & Technology Services” industry, but how does it contrast to its competitors? We will compare Allscripts Healthcare Solutions to related businesses based on the strength of its dividends, risk, analyst recommendations, valuation, earnings, profitability and institutional ownership.

Risk & Volatility

Allscripts Healthcare Solutions has a beta of 1.31, meaning that its stock price is 31% more volatile than the S&P 500. Comparatively, Allscripts Healthcare Solutions’ competitors have a beta of 1.33, meaning that their average stock price is 33% more volatile than the S&P 500.

Analyst Recommendations

This is a summary of recent recommendations for Allscripts Healthcare Solutions and its competitors, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Allscripts Healthcare Solutions 1 6 11 0 2.56
Allscripts Healthcare Solutions Competitors 76 405 780 12 2.57

Allscripts Healthcare Solutions currently has a consensus price target of $15.00, indicating a potential upside of 8.38%. As a group, “Medical Software & Technology Services” companies have a potential upside of 6.80%. Given Allscripts Healthcare Solutions’ higher possible upside, equities analysts plainly believe Allscripts Healthcare Solutions is more favorable than its competitors.

Insider and Institutional Ownership

60.2% of shares of all “Medical Software & Technology Services” companies are owned by institutional investors. 0.8% of Allscripts Healthcare Solutions shares are owned by insiders. Comparatively, 24.0% of shares of all “Medical Software & Technology Services” companies are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Earnings & Valuation

This table compares Allscripts Healthcare Solutions and its competitors top-line revenue, earnings per share and valuation.

Gross Revenue EBITDA Price/Earnings Ratio
Allscripts Healthcare Solutions $1.66 billion $160.09 million -13.06
Allscripts Healthcare Solutions Competitors $376.98 million $34.79 million 7.99

Allscripts Healthcare Solutions has higher revenue and earnings than its competitors. Allscripts Healthcare Solutions is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.


This table compares Allscripts Healthcare Solutions and its competitors’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Allscripts Healthcare Solutions -11.54% 5.97% 1.96%
Allscripts Healthcare Solutions Competitors -18.13% -11.71% -2.05%

About Allscripts Healthcare Solutions

Allscripts Healthcare Solutions, Inc. (Allscripts) delivers information technology (IT) solutions and services to help healthcare organizations. The Company operates through three segments: Clinical and Financial Solutions, Population Health, and Netsmart. The Clinical and Financial Solutions segment includes the sale of integrated clinical software applications and financial and information solutions. The Population Health segment includes the sale of health management and coordinated care solutions, which focus on hospitals, health systems, other care facilities and accountable care organizations (ACOs). The Netsmart segment provides software and technology solutions to the health and human services industry, which includes behavioral health, addiction treatment, intellectual and developmental disability services, child and family services and public health segments, as well as to post-acute home care organizations.

Receive News & Ratings for Allscripts Healthcare Solutions Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allscripts Healthcare Solutions Inc. and related companies with's FREE daily email newsletter.

Leave a Reply